Eafit Muscle Construction BCAA 4:1:1 80 Tablets
Original price was: $22.73.$15.91Current price is: $15.91.
- Shop with Confidence, Pay Safely
- Effortless solutions, excellent customer care.
- Uncompromising quality, every time.
- Discover a world of quality products.
Eafit Muscle Construction BCAA 4:1:1 80 Tablets is a dietary supplement formulated with valine, leucine and isoleucine, so-called “branched chain” amino acids that are naturally present in muscle tissue. They are essential to our body because it cannot synthesize them and must be provided by food or supplements.
The 4:1:1 ratio is the real ratio of muscle BCAA metabolism in the human body.
Complies with the anti-doping standard AFNOR NF V94-001.
No sugar, no aspartame.
Take 4 tablets a day, preferably 2 tablets 1h30 before training or testing and 2 tablets 1h30 after training with a large glass of water.
To be taken during intensive training or competition periods over 20 days, to be renewed at least 20 days apart.
Do not exceed the recommended daily intake.
In general, it is recommended to invite pregnant and lactating women to take the attachment of a health professional before any supplement.
It is advisable to consume this food supplement as part of a varied and balanced diet and a healthy lifestyle.
Close well after opening. Store away from heat and humidity.
Keep out of the reach of young children.
L-leucine (Hydroxypropylméthylcellulose), L-isoleucine, L-valine, Antiagglomérants : Cellulose microcristalline, Phosphate tricalcique, Stéarate de magnésium ; Chlorhydrate de pyridoxine.
| Composition | for 4 tablets | RI %* |
|---|---|---|
| BCAA 4:1:1 | 3600mg | – |
| L-Leucine | 2400mg | – |
| L-Isoleucine | 600mg | – |
| L-Valine | 600mg | – |
| Vitamin B6 | 0,21mg | 15% |
*Reference Intakes.
| EAN Code | 3518681008866 |
| Form | Capsule |
| Presentation | Pot |
| Contents | 80 tablets |
Be the first to review “Eafit Muscle Construction BCAA 4:1:1 80 Tablets”
Related products
After Effort
Athlete Accessories
Around Sport
Reviews
There are no reviews yet.